Bull case
Pulse Biosciences is attractive fundamentally because its nsPFA platform appears technically differentiated, with 5-second ablation, best-in-class procedural efficiency, and strong first-in-human outcomes across 141 patients, including 100% procedural success at six months, 96.2% at 12 months, and 90% freedom from AF/AFL/AT at one year. The U.S. opportunity is large and expanding, and the company’s rapid NANOPULSE-AF enrollment, now on track for completion in early Q4 2026 after starting in April 2026, suggests strong physician interest while reducing clinical execution risk ahead of a potential late 2027 or early 2028 approval. A capital-efficient partnership strategy, over 250 issued patents and more than 180 pending applications, plus additional revenue optionality from Vybrance and NANOCLAMP-AF, strengthen the long-term financial setup and support a constructive outlook.